Breaking Finance News

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has been upgraded to Hold in a statement by BidaskClub earlier today.

BidaskClub has upgraded Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to Hold in a statement released on Friday July 07, 2017.

On 7/4/2017, Zacks Investment Research released a statement on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) upped the target price from $0.00 to $19.00 that suggested an upside of 0.11%.

Having a price of $18.98, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) traded 1.84% higher on the day. With the last close up 31.65% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same period. ARNA has recorded a 50-day average of $21.42 and a two hundred day average of $15.97. Trade Volume was down over the average, with 596,252 shares of ARNA changing hands under the typical 1,079,330

Recent Performance Chart

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc. has with a one year low of $11.30 and a one year high of $27.86 and has a market capitalization of $0.

General Company Details For Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.